complexing the biologically active molecule with avidin or streptavidin, thereby forming a biologically active molecule-ligand complex, and 3) contacting the biologically active molecule-ligand complex with the cell surface, whereby the biologically active molecule is delivered into the cell.

20. (New) The method of claim 19 wherein the biologically active molecule is selected from the group consisting of proteins, enzymes, vitamins, vaccines, transcription factors, hormones, carbohydrates, lipids, oligonucleotides, and nucleic acids.

21. (New) The method of claim 19, wherein the biologically active molecules is a nucleic acid, the ligand is PEI conjugated to avidin or streptavidin and the surface receptor is biotin.

22. (New) A method for delivering a biologically active molecule to a cell comprising: 1) covalently linking biotin to the cell surface, wherein the biotin can act as a surface receptor, 2) complexing the biologically active molecule with avidin or streptavidin, thereby forming a biologically active molecule-ligand complex, and 3) contacting the biologically active molecule-ligand complex with the cell surface, whereby the biologically active molecule is delivered to the cell.

23. (New) The method of claim 22, wherein the biologically active molecule is selected from the group consisting of proteins, enzymes, vitamins, vaccines, transcription factors, hormones, carbohydrates, lipids, oligonucleotides, and nucleic acids.

24. (New) A method for delivering a biologically active molecule to a cell comprising:
1) covalently linking biotin to the cell surface, wherein the biotin can act as a surface receptor,
2) complexing the biologically active molecule with PEI conjugated to avidin or to streptavidin, wherein the biologically active molecule is a nucleic acid, thereby forming a biologically active

molecule-ligand complex, and 3) contacting the biologically active molecule-ligand complex with the cell surface, whereby the biologically active molecule is delivered to the cell.

25. (New) A composition comprising a nucleic acid-polyethyleneimine-streptavidin complex, wherein the polyethyleneimine is covalently linked to streptavidin.

26. (New) The composition of claim 22, wherein the nucleic acid is selected from the group consisting of DNA and oligonucleotide.

Please amend claim 7 as follows:

7. (Twice amended) The method of claim 1, wherein the biologically active molecules is a nucleic acid, the ligand is PEI conjugated to avidin or streptavidin and the surface receptor is biotin.

REMARKS

Claims 1-5 and 7-18 are pending in the present application. Claims 4-5, 8, and 11-14 are withdrawn from consideration. Claims 9-10 are allowed. Claims 1-2 and 15-16 are rejected. Claims 3, 7, and 17-18 are objected to as being dependent upon a rejected claim. New claims 19-26 are added. Support for new claims 19-26 can be found throughout the previous claims and the specification. New claim 19 is supported by earlier claims 1 and 3. New claims 20-21 are supported by earlier claims 2 and 7. New claim 22 is supported by earlier claims 15 and 17. New claim 23 is supported by earlier claim 16. New claim 24 is supported by earlier claims 15 and 18. Support for new claims 25 and 26 can be found in claims 9 and 10 and throughout the specification, but especially on page 8, lines 1 and 8-13. Support for amendment of claim 7 and for new claims 19, 21-22 and 24-25 to include recitation of streptavidin is also supported by this portion of the